Na+/K+ pump Inhibitors
1 drugsAbout Na+/K+ pump
The Na+/K+ pump, or sodium-potassium ATPase, is a plasma membrane protein that actively transports sodium ions out of and potassium ions into animal cells. This maintains electrochemical gradients essential for nerve impulse transmission, muscle contraction, and cell volume.
The Na+/K+ pump is a drug target in the cardiovascular area, but currently lacks genetic evidence linking variations to specific diseases. Further research could reveal connections and support novel therapeutics for diseases involving ion balance.
RUBY-FILL (JUBILANT) is the only FDA-approved drug targeting the Na+/K+ pump, approved in 2016. It is a small molecule used in cardiovascular applications.
Top Na+/K+ pump Drugs
JUBILANT is the only company with an approved drug targeting the Na+/K+ pump.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market development.
Na+/K+ pump Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Na+/K+ pump, using small molecule modality.
The modality landscape indicates a whitespace opportunity for developing novel biologics against this target.
Na+/K+ pump Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Na+/K+ pump. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Na+/K+ pump Drug Approval Timeline (2016 - 2016)
RUBY-FILL was the first and most recent drug approved in 2016, representing a 1-year approval span.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Na+/K+ pump. A trial counts if an approved drug acting on Na+/K+ pump is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.